Iterum Therapeutics News

Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024

DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics

GlobeNewswireMay 6 08:00 ET

Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), Iterum Therapeutics (ITRM)

TipRanksApr 30 06:20 ET

Express News | Iterum Therapeutics Resubmits New Drug Application To FDA For Oral Sulopenem

BenzingaApr 29 08:03 ET

Express News | Iterum Therapeutics PLC: Potential Approval Early Q4 2024

ReutersApr 29 08:01 ET

Express News | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

ReutersApr 29 08:00 ET

PERI, ITRM and CADL Among Pre-market Losers

Seeking AlphaApr 8 08:23 ET

On April 3, Iterum Therapeutics Received Letter From Nasdaq Indicating That It Is Not In Compliance With Nasdaq Listing Rule

On April 3, Iterum Therapeutics Received Letter From Nasdaq Indicating That It Is Not In Compliance With Nasdaq Listing Rule

BenzingaApr 5 16:36 ET

Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)

TipRanksApr 1 06:30 ET

Earnings Call Summary | Iterum Therapeutics(ITRM.US) Q4 2023 Earnings Conference

The following is a summary of the Iterum Therapeutics Plc (ITRM) Q4 2023 Earnings Call Transcript:Financial Performance:Iterum Therapeutics reported total operating expenses of $11.4 million in Q4 202

moomoo AIMar 28 10:27 ET · Conference Call

Express News | Iterum Therapeutics Q4 Adj EPS $(0.81) Beats $(0.93) Estimate

Moomoo 24/7Mar 28 08:50 ET

Iterum Therapeutics Resubmission of NDA for REASSURE on Track for Early 2Q >ITRM

Iterum Therapeutics Resubmission of NDA for REASSURE on Track for Early 2Q >ITRM

Dow JonesMar 28 07:02 ET

Iterum Therapeutics Non-GAAP EPS of -$0.81

Seeking AlphaMar 28 07:01 ET

Express News | Iterum Therapeutics Q4 2023 GAAP EPS $(0.94), Inline, Cash Position $23.9M

Moomoo 24/7Mar 28 07:01 ET

Iterum Therapeutics 4Q Loss $12.4M >ITRM

Iterum Therapeutics 4Q Loss $12.4M >ITRM

Dow JonesMar 28 07:00 ET

Earnings Scheduled For March 28, 2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. • Shimmick (NASDAQ:SHIM) is estimated

BenzingaMar 28 05:24 ET

Iterum Therapeutics's Earnings: A Preview

Iterum Therapeutics (NASDAQ:ITRM) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.Analysts estimate that Iterum

BenzingaMar 27 13:01 ET

Notable Earnings Before Thursday's Open

Seeking AlphaMar 27 09:11 ET

Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More

Seeking AlphaMar 24 08:01 ET

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics

GlobeNewswireMar 21 16:30 ET

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersXTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The market value of their outstanding shares is at $14.7 million. Leap Thera

BenzingaMar 20 17:34 ET